NR3C2 and Gynecomastia: Eplerenone itself is a small molecule suggested to selectively compete with aldosterone for mineralocorticoid receptor binding and as compared with the nonselective mineralocorticoid receptor antagonist Spironolactone has lower affinity for progesterone and androgen receptor binding which is associated with drug-induced gynecomastia, breast pain and impotence [17].